Metagenomi Therapeutics, Inc. Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost
Metagenomi Therapeutics, Inc. (MGX) had Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost of $81.76 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Debt and Equity Securities › Available-for-Sale Securities, Debt Maturities › Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost
us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis · last filed 2026-08-10
- 2026-06-30: Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost $81.76M.
- 2026-03-31: Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost $114.90M.
- 2025-12-31: Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost $118.82M.
- 2025-09-30: Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost $150.97M.
| Period end | Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost |
|---|---|
| 2026-06-30 | $81.76M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $114.90M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $118.82M 10-Q · filed 2026-08-10 |
| 2025-09-30 | $150.97M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $177.77M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $196.15M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $220.21M 10-K · filed 2026-03-05 |
| 2024-09-30 | $247.83M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $239.00M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $225.13M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $130.68M 10-K · filed 2025-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |